Century Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
25 N 38th St Fl 11, Philadelphia, Pennsy...Phone Number
(267) 817-5790Website
www.centurytx.comRevenue
-Stock Symbol
IPSCIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Century Therapeutics
Century Therapeutics is an innovative biotechnology company that is building an industry leading allogeneic iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development, and manufacturing capabilities to generate allogeneic, iPSC-derived NK and T cell therapies for cancer and autoimmune and inflammatory diseases.Explore more
Century Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Century Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Century Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Century Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Century Therapeutics is spiking on competitors!
Earning: See what the market has to say on Century Therapeutics recently announced quarterly report
Click to see if Century Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Century Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Check if Century Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Century Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Century Therapeutics
Compare insights from companies similar to Century Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Century Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Century Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Century Therapeutics.
Century Therapeutics financials insights
Gather financial insights about Century Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$250M
2021
Series C
$160M
2024
Other Financing Round
$60M
Century Therapeutics Tech Stack
A closer look at the technologies used by Century Therapeutics
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Medical Research, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Earnings, Pharmaceuticals, Finance, Investor Relations
Century Therapeutics News & Media
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the presentation of new preclinical data from CNTY-813, Century’s iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0, in an oral presentation at the American Diabetes Association (ADA) 86th ScienCentury Therapeutics Reports First Quarter Financial Results and Business Updates
PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the first quarter ended March 31, 2026, and recent business highlights.Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026 CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
Century Therapeutics reports FY2025 results; advances CNTY-813 (T1D) toward 4Q26 IND, CNTY-308 to clinic 2026; runway into 1Q29.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Century Therapeutics
Sign Up For FreeTo access detailed company insights
Century Therapeutics is an innovative biotechnology company that is building an industry leading allogeneic iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development, and manufacturing capabilities to generate allogeneic, iPSC-derived NK and T cell therapies for cancer and autoimmune an... Read More
